Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers

AIMS: Soticlestat, a first‐in‐class inhibitor of cholesterol 24‐hydroxylase (also known as cytochrome P450 46A1), is currently in development for the treatment of developmental and epileptic encephalopathies. Here, we report safety, tolerability, pharmacokinetic and pharmacodynamic outcomes from a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shining, Chen, Grace, Merlo Pich, Emilio, Affinito, John, Cwik, Michael, Faessel, Hélène M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305210/
https://www.ncbi.nlm.nih.gov/pubmed/35001412
http://dx.doi.org/10.1111/bcp.15225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305210/
https://www.ncbi.nlm.nih.gov/pubmed/35001412
http://dx.doi.org/10.1111/bcp.15225

Ejemplares similares